The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Due to the COVID-19 pandemic, the global Autoimmune Disorder Drug Delivery Device market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Autoimmune Disorder Drug Delivery Device market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Autoimmune Disorder Drug Delivery Device landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Pen Injectors accounting for % of the Autoimmune Disorder Drug Delivery Device global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While In-house Manufacturing segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Autoimmune Disorder Drug Delivery Device include AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Biogen Inc., Merck KGaA, Bayer AG and Johnson & Johnson Services Inc., etc. In terms of revenue, the global 3 largest players have a % market share of Autoimmune Disorder Drug Delivery Device in 2021.
This report focuses on Autoimmune Disorder Drug Delivery Device volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Autoimmune Disorder Drug Delivery Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Autoimmune Disorder Drug Delivery Device Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Pen Injectors
Auto-Injectors
Prefilled Syringes
Vials
Segment by Application
In-house Manufacturing
Outsourced Manufacturing
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
AbbVie Inc.
Amgen Inc.
F. Hoffmann- La Roche Ltd.
Novartis AG
GlaxoSmithKline Plc
Biogen Inc.
Merck KGaA
Bayer AG
Johnson & Johnson Services Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lily and Company
Sanofi S.A.
Takeda Pharmaceutical Company Limited